EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study

Ayako Miyazawa, Ryusuke Nambu iD, Hirotaka Shimizu, Takahiro Kudo iD, Takuya Nishizawa, Hideki Kumagai, Shin-Ichiro Hagiwara, Emiri Kaji, Tatsuki Mizuochi, Shingo Kurasawa, Fumihiko Kakuta, Takashi Ishige und 3 weitere

Inflammatory Bowel Diseases · 2025

DOI: 10.1093/ibd/izae266 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Ayako Miyazawa und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2, Shintoshin, Chuo-ku, Saitama City, Saitama 330-8777, Japan. Hauptthemen laut MEDLINE: Mesalamine, Colitis, Ulcerative, Immunosuppressive Agents, Proctitis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although ulcerative proctitis (UP) in children is considered relatively mild, some patients have proximal disease extension and require immunosuppressive treatment. We investigated clinical characteristics and course of refractory UP in a multicenter pediatric cohort.

Methods

Analyzing data obtained between 2013 and 2022 at 10 institutions specializing in pediatric inflammatory bowel disease, we elucidated natural history and factors predicting a need for immunosuppressive UP treatment. We compared patients given immunosuppressants and/or biologic agents (immunosuppressive treatment group) with those given 5-aminosalicylic acid (5-ASA) alone (5-ASA group).

Results

Fifty-five patients were followed for 3.5 years. The median Pediatric Ulcerative Colitis Activity Index at diagnosis was 20. The commonest treatment, 5-ASA suppository monotherapy in 40% of patients, showed the worst compliance. Clinical remission was achieved at least once in 95% of all patients. Disease extension beyond the splenic flexure occurred in 51%. Immunosuppressive treatment was given to 37%; biologic agents were used for 18%. Rates of endoscopically demonstrated inflammation, including Ra/Rs at diagnosis and extension beyond the left-sided colon, were higher in the immunosuppressive treatment group (70% vs 38%, P < 0.05; 95% vs 27%, P < 0.0001). The log-rank test and multivariate Cox proportional hazards regression showed that time to first clinical remission exceeding 3 months predicted the need for biologics.

Conclusion

The typical initial treatment of pediatric UP was 5-ASA suppositories, despite poor compliance. Biologics or other immunosuppressive treatments were needed in 37% of patients. Close follow-up with adjustment of treatment should be considered in children with UP as its clinical course varies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesalamineColitis, UlcerativeImmunosuppressive AgentsProctitisAnti-Inflammatory Agents, Non-SteroidalHumansMaleFemaleChildPrognosisAdolescentFollow-Up StudiesChild, PreschoolRetrospective StudiesSeverity of Illness IndexCohort StudiesRemission Induction

Stichwörter der Autor:innen

inflammatory bowel diseasepediatric ulcerative colitisproctitis

Substanzen

MesalamineImmunosuppressive AgentsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, 1-2, Shintoshin, Chuo-ku, Saitama City, Saitama 330-8777, Japan.
  • Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, 2-10-1, Okura, Setagaya-City, Tokyo 157-8535, Japan.
  • Department of Pediatrics, Juntendo University Faculty of Medicine, 3-1-3, Hongo, Bunkyo City, Tokyo 113-0033, Japan.
  • Department of Pediatrics, Gunma University Graduate School of Medicine, 3-39-15, Showamachi, Maebashi, Gunma 371-8511, Japan.
  • Department of Pediatrics, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke, Tochigi 329-0431, Japan.
  • Department of Gastroenterology, Nutrition and Endocrinology, Osaka Women's and Children's Hospital, 840, Murodocho, Izumi, Osaka 594-1101, Japan.

ORCID-Profile: Ryusuke Nambu, Takahiro Kudo, Itaru Iwama, Katsuhiro Arai

Zitieren

APA

Miyazawa, A., Nambu, R., Shimizu, H., Kudo, T., Nishizawa, T., Kumagai, H., Hagiwara, S. I., Kaji, E., Mizuochi, T., Kurasawa, S., Kakuta, F., Ishige, T., Shimizu, T., Iwama, I., & Arai, K. (2025). Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae266

Vancouver

Miyazawa A, Nambu R, Shimizu H, Kudo T, Nishizawa T, Kumagai H, et al. Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae266

BibTeX
@article{Miyazawa2025,
  author = {Miyazawa, Ayako and Nambu, Ryusuke and Shimizu, Hirotaka and Kudo, Takahiro and Nishizawa, Takuya and Kumagai, Hideki and Hagiwara, Shin-Ichiro and Kaji, Emiri and Mizuochi, Tatsuki and Kurasawa, Shingo and Kakuta, Fumihiko and Ishige, Takashi and Shimizu, Toshiaki and Iwama, Itaru and Arai, Katsuhiro},
  title = {Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  doi = {10.1093/ibd/izae266}
}
Kostenlos starten →